Patrick Campbell

A study examining associations between coffee metabolites and risk of NAFLD severity suggests people with type 2 diabetes had a lower risk of fibrosis and more severe NAFLD based on increased coffee consumption.

An analysis of NHANES data from 1999-2018 details the progress made with regard to cholesterol management on a population level but also provides insight into areas where room for improvement still exists.

Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.

A simulation study including both cardiologists and pulmonologists found providers failed to properly diagnose pulmonary hypertension more than 50% of the time.

Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.

An analysis of data from type 1 diabetes prevention trials is shedding new light on factors associated with increased and decreased likelihood of screening for type 1 diabetes among participants considered eligible for each trial.

A systematic review and meta-analysis of observational studies of people with diabetes suggest more than 1-in-4 also had a diagnosis of osteoporosis.

Applying a statistical model to estimate the effects of reducing sodium intake at a population level in Australia, investigators suggest adherence to World Health Organization benchmarks could prevent 6900 deaths from CVD, CKD, and stomach cancers annually.

Using data from 2 large prospective studies, a Harvard-led team estimates the impact of adherence to a group of healthy eating patterns on risk of all-cause and cause-specific mortality.

Using data from 18 trials with more than 1400 participants, a systematic review and meta-analysis offer clinicians an overview of the effects of SGLT2 inhibitor use on body composition in people with type 2 diabetes.

Data from a 2019 survey of more than 5000 cardiologists across the globe suggests 28% of the field may be experiencing some form of mental health condition, with results also shedding light on predictors of mental health conditions.

Using data from more than 25,000 preschool-aged children in Sweden provides an overview in trends of weight gain and BMI changes that may have impacted pediatric populations during the COVID-19 pandemic.

Using real-world data from the US, Japan, and Sweden provides insight into contemporary trends in GDMT use, including initiation, uptitration, and discontinuation, following hospitalization among patients with heart failure with reduced ejection fraction.

Exploratory analyses of data from the Look AHEAD trial suggest maintaining an HbA1c level of 7% or less was associated with smaller increases in frailty index over the 8-year study period when compared to their counterparts with an HbA1c level of 8% or greater.

Released on January 3, the American College of Physician's living osteoporosis guideline represents the organization's first update on the topic since 2017 and includes 6 specific recommendations for pharmacologic management of osteoporosis or low bone mass.

Jesse Morse, MD, a sports medicine specialist, discusses commotio cordis and how to effectively communicate with athletes and parents of young athletes about the diagnosis in the wake of an incident where a player collapsed during a recent NFL game.

As physician demands continue to climb in the high-demand specialty, patient-reported outcomes have emerged as a viable tool in assessment and care.

Reflections on a century's worth of developments toward a major breakthrough in T1D this year.

On November 17, the US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.

Data from a phase 2 trial presented at ACR Convergence 2022 provides clinicians with insight into the effects of deucravacitinib, a TYK2 inhibitor, in patient populations with systemic lupus erythematosus.

A pair of studies leveraging NIS data detail the risk of cardiovascular complications during delivery admissions among pregnant persons with a history of systemic lupus erythematosus or use of assisted reproductive technologies relative to their counterparts who did not.

Following a session examining the application of the latest iterations of cardiometabolic health guidelines, Diana Isaacs, PharmD, discusses how the evolving role of diabetes, and recognition of this role, in cardiovascular disease is reflected at the American Heart Association 2022 Scientific Sessions.

Viet Le, PA-C, discusses the results of a study examining characteristics and outcomes among pregnant statin users from EHR data recorded at Intermountain Healthcare medical centers.

Results of the CTS-AMI study presented at AHA 22 suggests tongxiluo, which is an herbal medicine compound used in China, could reduce risk of cardiac events and mortality following a heart attack.

A substudy of the PRO-HF study indicates incorporation of KCCQ-12 scores was associated with an improved patient experience and a greater understanding of symptoms.

Data from the Diuretic Comparison Project suggests chlorthalidone did not provide a reduction in cardiovascular risk or all-cause mortality compared with use of hydrochlorothiazide in older patients with hypertension.

An analysis of nationally representative data from AHA 2022 suggests most older adults in the US with hypertension were not receiving adequate treatment intensification set forth in US and international guidelines.

The approval indicates the subcutaneous loop diuretic for the at-home treatment of congestion in adults with NYHA Class II/III chronic heart failure.